FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2071944485> ?p ?o ?g. }

• W2071944485 endingPage "27204" @default.
• W2071944485 startingPage "27199" @default.
• W2071944485 abstract "Chemical studies have shown the occurrence of the deaminated sialic acid 2-keto-3-deoxy-d-glycero-d-galacto-nononic acid (KDN) in paired samples of blood obtained from mothers and newborns of healthy human individuals. Most of the KDN was found in red blood cells, although low levels were detected in mononuclear cells. NoN-glycolylneuraminic acid was detected. Unexpectedly, nearly all of the KDN in fetal cord and matched maternal red blood cells was present as the free sugar and comparatively little occurred conjugated or as cytidine 5′-KDN phosphate. The amount of free KDN in fetal newborn red blood cells was 2.4-fold higher than in red blood cells from the mothers or from healthy nonpregnant women. Free KDN was also identified in normal human ovaries, in ovarian tumors, and in ascites cells obtained from ovarian cancer patients. Importantly, as in fetal cord red blood cells, a distinguishing feature of KDN expression in ovarian tumor cells was an elevated level of free KDN compared with normal controls. A positive correlation was found between an increase in the ratio of free KDN/N-acetylneuraminic acid in ovarian adenocarcinomas and the stage of malignancy. This was particularly evident in tumor cells isolated from the ascites fluid. The central importance of these new findings is 2-fold. First, they show that free KDN is a minor but ubiquitous sialic acid in human red blood cells and that its elevated expression in red blood cells from fetal cord blood compared with maternal red blood cells may be developmentally related to blood cell formation during embryogenesis. Second, the enhanced expression of KDN in ovarian cancer cells suggests that this sialic acid, like the α2,8-linked polysialic acid glycotope, may be an oncofetal antigen in these tumors and thus could be an “early warning” signal for onset of disease and/or a marker for detection of recurrence of disease. These new findings highlight the importance of elucidating the role that KDN and KDN-containing glycoconjugates may play in normal development and malignancy. Chemical studies have shown the occurrence of the deaminated sialic acid 2-keto-3-deoxy-d-glycero-d-galacto-nononic acid (KDN) in paired samples of blood obtained from mothers and newborns of healthy human individuals. Most of the KDN was found in red blood cells, although low levels were detected in mononuclear cells. NoN-glycolylneuraminic acid was detected. Unexpectedly, nearly all of the KDN in fetal cord and matched maternal red blood cells was present as the free sugar and comparatively little occurred conjugated or as cytidine 5′-KDN phosphate. The amount of free KDN in fetal newborn red blood cells was 2.4-fold higher than in red blood cells from the mothers or from healthy nonpregnant women. Free KDN was also identified in normal human ovaries, in ovarian tumors, and in ascites cells obtained from ovarian cancer patients. Importantly, as in fetal cord red blood cells, a distinguishing feature of KDN expression in ovarian tumor cells was an elevated level of free KDN compared with normal controls. A positive correlation was found between an increase in the ratio of free KDN/N-acetylneuraminic acid in ovarian adenocarcinomas and the stage of malignancy. This was particularly evident in tumor cells isolated from the ascites fluid. The central importance of these new findings is 2-fold. First, they show that free KDN is a minor but ubiquitous sialic acid in human red blood cells and that its elevated expression in red blood cells from fetal cord blood compared with maternal red blood cells may be developmentally related to blood cell formation during embryogenesis. Second, the enhanced expression of KDN in ovarian cancer cells suggests that this sialic acid, like the α2,8-linked polysialic acid glycotope, may be an oncofetal antigen in these tumors and thus could be an “early warning” signal for onset of disease and/or a marker for detection of recurrence of disease. These new findings highlight the importance of elucidating the role that KDN and KDN-containing glycoconjugates may play in normal development and malignancy. sialic acid 2-keto-3-deoxy-d-glycero-d-galacto-nononic acid N-acetylneuraminic acid N-glycolylneuraminic acid cytidine 5′-KDN phosphate 1,2-diamino-4,5-methylenedioxybenzene high performance liquid chromatography mannose mannose 6-phosphate KDN 9-phosphate cytidine 5′-sialic acid phosphate. Expression of sialic acid (Sia) (1Varki A. Glycobiology. 1992; 2: 24-40Crossref Scopus (477) Google Scholar)1 residues on glycoconjugates is of critical importance in normal development and differentiation because these sugar molecules appear to mediate a variety of specific biological functions (1Varki A. Glycobiology. 1992; 2: 24-40Crossref Scopus (477) Google Scholar, 2Schauer R. Kamerling J.P. Neuberger A. Van Deenen L.L.M. New Comprehensive Biochemistry: Glycoproteins. 29B. Elsevier Publishing Co., Amsterdam1997: 243-402Google Scholar).N-Acetylneuraminic acid (Neu5Ac) is the most common occurring Sia, and more than 40 naturally occurring derivatives have been described. The temporal appearance and disappearance of Sia at different stages during normal development and on different cell types is a highly regulated and dynamic process (3Hakomori S. Adv. Cancer Res. 1989; 52: 257-331Crossref PubMed Scopus (1076) Google Scholar). It is also believed that Sia plays a central role in malignant transformation, because changes in the levels, type, or linkage of Sia in tumor cell glycoconjugates can affect the malignant potential of tumors (4Takano R. Muchmore E. Dennis J.W. Glycobiology. 1994; 4: 665-674Crossref PubMed Scopus (74) Google Scholar). For example, some lymphoid tumors expressing N-glycolylneuraminic acid (Neu5Gc) are highly metastatic (4Takano R. Muchmore E. Dennis J.W. Glycobiology. 1994; 4: 665-674Crossref PubMed Scopus (74) Google Scholar), and many sialylated glycoconjugates are stage-specific antigens that can be re-expressed on cancer cell as “oncofetal” or “oncodevelopmental” antigens (3Hakomori S. Adv. Cancer Res. 1989; 52: 257-331Crossref PubMed Scopus (1076) Google Scholar). The α2,8-linked polySia glycotope is one such oncodevelopmental, tumor-associated antigen. The cell surface expression of polysialylated neural cell adhesion molecules is positively correlated with increased malignancy in a number of human tumors, including Wilms tumor (5Roth J. Zuber C. Wagner P. Taatjes D.J. Weisgerber C. Heitz P.U. Goridis C. Bitter-Suermann D. Proc. Natl. Acad. Sci. U. S. A. 1988; 85: 2999-3003Crossref PubMed Scopus (173) Google Scholar), human neuroblastomas, some of which are metastatic to bone and brain (6Livingston B.D. Jacobs J.L. Glick M.C. Troy F.A. J. Biol. Chem. 1988; 263: 9443-9448Abstract Full Text PDF PubMed Google Scholar, 7Glick M.C. Livingston B.D. Shaw G.W. Jacobs J.L. Troy F.A. Evans A.E. Knudson A.G. Seeger R.C. D'Angio G.J. Advances in Neuroblastoma Research. John Wiley & Sons, Inc., New York1991: 267-274Google Scholar), malignant lymphoma (8Kern W.F. Spier C.M. Miller T.P. Grogan T.M. Leuk. Lymphoma. 1993; 12: 1-10Crossref PubMed Scopus (41) Google Scholar, 9Grogan T. Guptil J. Mullen J. Ye J. Hanneman E. Vela L. Frutiger Y. Miller T. Troy F.A. Lab. Invest. 1994; 70 (Abstr. 637): 110Google Scholar), acute myeloid leukemia (10Scott A.A. Kopecky K.J. Grogan T.M. Head D.R. Troy F.A. Mullen J. Ye J. Appelbaum F.R. Theil K.S. Willman C.L. Lab. Invest. 1994; 70 (Abstr. 695): 120Google Scholar), and in head and neck malignancies (11Gandour-Edwards R. Deckard-Janatpour K. Ye J. Donald P.J. Troy F.A. Med. Pathol. 1995; 8 (Abstr. 582): 101Google Scholar). The importance of the polySia glycotope in normal and malignantly transformed human tissues was recently reviewed (12Troy F.A. Rosenberg A. Biology of the Sialic Acids. Plenum Press, New York1995: 95-144Crossref Google Scholar). The general involvement of carbohydrate chains in metastasis and prognosis of human carcinomas and the roles of tumor associated carbohydrate antigens in cell adhesion during tumor metastasis have also been recently summarized (13Muramatsu T. Glycobiology. 1993; 3: 291-296Crossref PubMed Scopus (140) Google Scholar, 14Fukuda M. Cancer Res. 1996; 56: 2237-2244PubMed Google Scholar). In 1986, we discovered the occurrence of deaminated neuraminic acid (2-keto-3-deoxy-d-glycero-d-galacto-nononic acid; KDN; Structure FS1) in fish eggs as a new class of Sia (15Nadano D. Iwasaki M. Endo S. Kitajima K. Inoue S. Inoue Y. J. Biol. Chem. 1986; 261: 11550-11557Abstract Full Text PDF PubMed Google Scholar). Subsequent studies showed that KDN was expressed on cells ranging in evolutionary diversity from microbes to lower vertebrate species, in some cases as 9-O-acetyl-KDN (16Iwasaki M. Inoue S. Troy F.A. J. Biol. Chem. 1990; 265: 2596-2602Abstract Full Text PDF PubMed Google Scholar), and recently in mammalian cells and tissues (Ref. 17Inoue S. Kitajima K. Inoue Y. J. Biol. Chem. 1996; 271: 24341-24344Abstract Full Text Full Text PDF PubMed Scopus (71) Google Scholar and references therein). We now provide unambiguous evidence for the occurrence of KDN in normal human red blood cells and in normal and malignant ovarian tissues. An increased expression of free KDN in fetal cord red blood cells from newborns, compared with maternal red blood cells, and its elevation in ovarian tumors compared with normal ovarian tissues, are central new findings that highlight the importance of elucidating the role that KDN and KDN-containing glycoconjugates may play in normal development and malignancy. 1 ml each of paired maternal and fetal cord blood was collected from full term parturients at the Tri-Service General Hospital, Taiwan in anticoagulant coated-tubes that had been treated with EDTA. All patients consented to the blood test. Maternal blood was collected at the beginning of labor and fetal cord blood was collected immediately after delivery before placenta separation. Plasma and red blood cells were separated by centrifugation at 12,000 rpm for 10 min. Adult blood (10 ml each) was collected from healthy female donors (age ranged 18–37) in heparinized, anticoagulant tubes. All procedures were carried out at 4 °C. Red blood cells were collected from whole blood by centrifugation at 2,500 rpm for 15 min and washed three times with 3 volumes of 0.85% NaCl, 5 mm Tris-HCl (pH 7.4). Washed red blood cells were lyzed with 9 volumes of 10 mm Tris-HCl (pH 7.4) and centrifuged at 25,000 × g for 30 min. The supernatant was removed, and the pelleted ghosts were washed with 10 mm Tris-HCl (pH 7.4) until free of hemoglobin. All tissues and body fluids were obtained from biopsy or surgical dissection and stored at −80 °C until use. Approximately 8–50 mg of tissue or cells were used for each analysis. Ascites cells were collected by centrifugation of ascites at 12,000 rpm and washed with phosphate-buffered saline (pH 7.4). Free Sia and CMP-Sia were separated from soluble glycoproteins in the red blood cells lysates by ethanol precipitation. To 2.0 ml of the lysate, corresponding to 0.2 ml of red blood cells, 8.0 ml of cold absolute ethanol were added. The mixture was kept on ice for about 1 h before centrifugation at 3,000 rpm for 15 min. This allowed separation of free Sia and CMP-Sia from the soluble glycoproteins that were precipitated by ethanol (18Muchmore E.A. Glycobiology. 1992; 2: 337-343Crossref PubMed Scopus (28) Google Scholar). The precipitate was washed three times with cold 80% ethanol, and the supernatant fractions were combined. The ethanol-soluble fraction was dried by evaporation. The residue was dissolved in 500 μl of water, and 50 μl (corresponding to 20 μl of red blood cells) were applied to a Bio-Rad AG-1 column. The fraction eluting with 0.7 m formic acid was subjected to quantitative Sia determination by HPLC analysis of the DMB derivatives, as described below. 1 ml of 90% phenol was added to 2 ml of the red blood cells lysate, and the mixture was stirred vigorously at room temperature. After centrifugation at 3,000 rpm, the supernatant was passed through a Bio-Rad AG-1 column (1.5 × 2 cm). The Sia, which eluted with 3 column volumes of 0.7 m formic acid, were analyzed as by HPLC as their DMB derivatives (see “Sialic Acid and Protein Analysis”). All procedures were carried out at 4 °C unless stated otherwise. Ovarian tissues (8–50 mg) were cut into small pieces in 0.5–1.0 ml of TBS buffer (0.01 m Tris-HCl buffer (pH 8.0) containing 0.15m NaCl) and homogenized with a Polytron homogenizer (Kinematica, Littau, Switzerland). The homogenate was centrifuged at 20,000 × g for 20 min, and the pellet was re-homogenized in TBS buffer and centrifuged again at 20,000 ×g for 20 min. The pellet was designated 20P. The supernatant fractions were combined and centrifuged at 100,000 × gfor 1 h. The pellet from this sedimentation was designated 100P. Four volumes of ethanol were added to the supernatant fractions, and after 2.0 h on ice, the precipitate was collected by centrifugation and washed three times with cold 80% ethanol. The combined supernatant fractions were dried under vacuum at 30 °C, and the total amount of Sia was quantitatively determined as their DMB derivatives by HPLC analysis, as described below. The total amount of Sia in the 20P and 100P fractions were also quantitatively determined after mild acid hydrolysis, as described below. The amount of Sia was quantitatively determined as their DMB derivatives by HPLC, as described previously (17Inoue S. Kitajima K. Inoue Y. J. Biol. Chem. 1996; 271: 24341-24344Abstract Full Text Full Text PDF PubMed Scopus (71) Google Scholar, 19Hara S. Yamaguchi M. Takemori Y. Furuhata K. Ogura H. Nakamura M. Anal. Biochem. 1989; 179: 162-166Crossref PubMed Scopus (246) Google Scholar). For the analysis of bound Sia, samples were first hydrolyzed in 0.1 m HCl for 1.0 h at 80 °C. The HCl was removed by evaporation. In some samples, the hydrolysate was treated with a Bio-Rad AG-1 column before derivatization. The DMB derivatives were resolved on TSK-gel ODS-120T (Tosoh, Tokyo, Japan) or Micorsorb C18 (Rainin, Woburn, MA) columns on a Jasco series 900 or Hewlett Packard series 1100 HPLC systems. The fluorescent detectors were set at 373 nm for excitation and 448 nm for emission. The columns (inner diameter, 250 × 4.6 cm) were eluted isocratically at room temperature with a mixture of methanol/acetonitrile/water (7:5:88). The amount of protein was estimated with the bicinchoninic acid kit (Pierce) using bovine serum albumin as a standard. The amount of total KDN and Neu5Ac in red blood cells isolated from 14 matched pairs of fetal cord and maternal blood samples was quantitatively determined after mild acid hydrolysis by a highly sensitive fluorescence-assisted HPLC method (17Inoue S. Kitajima K. Inoue Y. J. Biol. Chem. 1996; 271: 24341-24344Abstract Full Text Full Text PDF PubMed Scopus (71) Google Scholar,19Hara S. Yamaguchi M. Takemori Y. Furuhata K. Ogura H. Nakamura M. Anal. Biochem. 1989; 179: 162-166Crossref PubMed Scopus (246) Google Scholar). As shown in Fig. 1, the mean values of total KDN in fetal cord red blood cells was approximately 2.4-fold higher than the levels in matched maternal red blood cells (1.4 ± 0.67 μg/ml versus 0.59 ± 0.23 μg/ml). Further, the relative KDN levels were determined to be on average 2.2 and 0.94 mol % of the Neu5Ac levels in fetal cord and maternal red blood cells, respectively. Thus, these results show a statistically significant higher level of KDN in umbilical cord red blood cells from neonates compared with their matched maternal red blood cells. This difference appears to be even more significant when compared with the small difference found between the levels of Neu5Ac in cord and maternal red blood cells, determined to be 69 ± 21 and 74 ± 20 μg/ml, respectively. It is interesting to note that the relative amount of KDN in human red blood cells is 3.6-fold higher than that in adult rat red blood cells (0.94 mol % versus 0.26 mol % of the total Sia). To determine whether the high level of KDN expression in cord and maternal red blood cells was restricted to these cells or was possible due to contamination of this fraction with other serum components, we analyzed both plasma and red blood cells fractions that were separated from cord and maternal blood by centrifugation. The results clearly showed that a major proportion of KDN was associated with both the cord and adult red blood cells (95 and 86%, respectively; Table I). Essentially the same results were obtained when cord and maternal blood were separated by density gradient centrifugation in Ficoll-Paque (Amersham Pharmacia Biotech). Although a small proportion of KDN was associated with the mononuclear cell fraction, only negligible amounts were found in plasma, which may have been due to red blood cell lysis during fractionation. In this experiment, plasma contained about 80% of the total blood Neu5Ac. We also sought to determine the distribution of KDN and Neu5Ac in the cytosolic and membrane fractions isolated from fetal cord and adult red blood cell lysates. The results from these studies showed that about 98% of the KDN was in the cytosolic fraction in both adult and cord red blood cells. In marked contrast, about 90% of the Neu5Ac was found in the membrane fraction (Table I). On the basis of these results we conclude that KDN, unlike Neu5Ac, is uniquely localized to the cytosolic fraction in both fetal cord and adult red blood cells.Table IQuantitative determination of the levels of KDN and Neu5Ac in the plasma, cytosol, and membrane fractions of fetal cord and adult red blood cellsCord (n = 7)Adult (n = 6)KDNNeu5AcKDNNeu5Acng/mlμg/mlng/mlμg/mlPlasma34 ± 1397 ± 1622 ± 13114 ± 5.0RBCs610 ± 47043 ± 16140 ± 8054 ± 5.9RBC supernatant740 ± 3304.0 ± 2.299 ± 592.6 ± 1.7RBC membrane16 ± 427 ± 1.73 ± 227 ± 1.9The plasma was the supernatant obtained after sedimentating red blood cells from heparinized blood. The values recorded are the means ± S.D. The values for KDN in both cord and adult red blood cells determined in this series of experiments were lower than those calculated from the data shown in Fig. 1 and those obtained by isolation (Table II). The values obtained in these latter two experiments were statistically more reliable because of the larger number of samples (Fig. 1) and red blood cells (Table II). RBC, red blood cell. Open table in a new tab The plasma was the supernatant obtained after sedimentating red blood cells from heparinized blood. The values recorded are the means ± S.D. The values for KDN in both cord and adult red blood cells determined in this series of experiments were lower than those calculated from the data shown in Fig. 1 and those obtained by isolation (Table II). The values obtained in these latter two experiments were statistically more reliable because of the larger number of samples (Fig. 1) and red blood cells (Table II). RBC, red blood cell. To determine whether the high levels of KDN present in the supernatant fraction of red blood cells lysates was free or bound to soluble glycoproteins, ethanol and phenol were used separately to precipitate any soluble proteins. Essentially all of the KDN in the supernatant fractions derived from adult or cord red blood cell lysates was recovered in the ethanol-soluble fraction and the water-soluble fraction after phenol treatment, suggesting that KDN either existed as the free sugar, as CMP-KDN or associated with low molecular weight components. Unlike KDN, less than 10% of the total Neu5Ac found in red blood cells appeared in the ethanol-soluble fraction, and this amount was similar for cord and adult red blood cells. To determine the chemical nature of KDN and Neu5Ac that was present in the cytosol of cord and adult red blood cell lysates, the ethanol-soluble fractions were applied separately to Q-Sepharose columns equilibrated with 0.02 m Tris-HCl (pH 9.0) in the cold. The material that bound to the column was eluted with a linear gradient of NaCl. The eluted fractions were monitored for the presence of KDN and Neu5Ac by HPLC. All of the KDN eluted in the column flow-through fraction from both fetal and adult red blood cells, whereas 63% of the Neu5Ac in both fetal and adult red blood cells bound to the gel and was eluted with 0.1–0.25 m NaCl. The flow-through fraction was then applied to a Bio-Gel P-2 column and eluted with 0.05 mNaCl. The chemical nature of the eluted (free) Sia was shown to be exclusively free Neu5Ac (accounted for 37% of the total) and KDN as determined by HPLC analysis of its DMB derivative (Fig. 2). As shown in Fig. 2, KDN and Neu5Ac were eluted under discrete peaks that coincided with the peaks of authentic KDN and Neu5Ac, respectively. This separation thus provided an unambiguous method to quantitatively determine the amount and chemical form of each Sia derivative in the cytosol of fetal and adult red blood cells. The Neu5Ac-containing fraction from maternal red blood cells that bound to Q-Sepharose and contained about two-thirds of the Neu5Ac was subsequently eluted from the Bio-Gel P-2 column in two broad peaks, which preceded the peak of free Neu5Ac. This elution profile would be that expected for Neu5Ac-containing small glycoproteins soluble in 80% ethanol. The nature of these Sia-containing structures was not further studied. No CMP-KDN or CMP-Neu5Ac was detected in the ethanol-soluble fraction from either fetal or adult red blood cells, even when using sensitive and specific HPLC methods and separation methods that avoided hydrolysis of labile sugar nucleotide linkages (20Petrie III, C.R. Korytnyk W. Anal. Biochem. 1983; 131: 153-159Crossref PubMed Scopus (31) Google Scholar, 21Spiegel L.B. Hadjimichael Rossomando E.F. J. Chromatogr. 1992; 573: 23-27Crossref PubMed Scopus (6) Google Scholar). The quantitative levels of free and bound KDN and Neu5Ac in cord and maternal red blood cells, determined after chromatographic separation of their DMB derivatives (Fig. 2), are summarized in Table II. These findings provide unambiguous evidence for the occurrence of free KDN in normal human red blood cells and its elevated expression in matched fetal cord red blood cells. On the basis of these new findings, we sought to determine whether free KDN was expressed in other normal human cells, e.g. ovarian tissues, and, if so, if this expression differed in ovarian cancer.Table IIQuantitative determination of free and bound KDN and Neu5Ac in the ethanol-soluble fraction isolated from fetal cord and maternal red blood cell lysates after chromatographic separation of each sialic acid componentKDNNeu5AcFreeBoundFreeBoundμg ml−1red blood cellsCord1.600.71.2Maternal0.900.40.7Pooled fetal cord red blood cells, 40 ml from three neonates, and maternal red blood cells, 14 ml from five mothers, were lyzed under hypotonic conditions, and the supernatant fractions were treated with ethanol to precipitate soluble glycoproteins, as described in the text. Each ethanol soluble fraction was applied to a Q-Sepharose column, and the flow through fraction that contained unbound sialic acids was subjected to Bio-Gel P-2 chromotography. KDN and Neu5Ac were separated and quantitatively determined as their DMB derivatives by HPLC, as described under “Experimental Procedures.” Open table in a new tab Pooled fetal cord red blood cells, 40 ml from three neonates, and maternal red blood cells, 14 ml from five mothers, were lyzed under hypotonic conditions, and the supernatant fractions were treated with ethanol to precipitate soluble glycoproteins, as described in the text. Each ethanol soluble fraction was applied to a Q-Sepharose column, and the flow through fraction that contained unbound sialic acids was subjected to Bio-Gel P-2 chromotography. KDN and Neu5Ac were separated and quantitatively determined as their DMB derivatives by HPLC, as described under “Experimental Procedures.” A quantitative comparison of the amount of KDN and Neu5Ac in normal human ovaries, ovarian tumors, and in ascites cells isolated from ovarian cancer patients is shown in Table III. Based on these initial studies, our findings support the following important conclusions: (a) Normal human ovarian tissue expressed KDN in amounts comparable with the amount found in adult human red blood cells. (b) The level of total KDN expressed was elevated 2.6-fold in ascites cells obtained from ovarian cancer patients, while showing a 55% increase in the ovarian tumor cells. These ascites cells showed a 5-fold higher KDN/Neu5Ac ratio than normal ovarian cells (1.8 versus 0.36 mol/100 mol). However, the values of the total KDN/Neu5Ac ratio for normal and ovarian tumor cells were similar (0.36 versus 0.41 mol/100 mol), perhaps because the Neu5Ac levels are reported to be elevated in some ovarian tumors (22Feijoo C. Páez de la Cadena M. Rodrı́guez-Berrocal F.J. Martı́nez-Zorzano V.S. Cancer Lett. 1997; 112: 155-160Crossref PubMed Scopus (37) Google Scholar). (c) Like human red blood cells, the major proportion of KDN was found as the free sugar in both normal and ovarian tumor cells. Based on the mean values shown in Table III, 80 and 89% of the total KDN from normal and ovarian or ascites tumor cells, respectively, was found in the ethanol-soluble fractions. In contrast, the Neu5Ac levels in the ethanol-soluble fraction accounted for only 21, 6, and 10% of the total Sia in normal and ovarian tumor and ascites cells, respectively. Thus, this reciprocal difference in the percentage of distribution of KDN and Neu5Ac in the ethanol-soluble fraction between normal and ovarian tumor cells, which led to a 4.2-fold increase in the KDN/Neu5Ac ratio in ovarian tumor cells and a 77-fold increase in ascites tumor cells, is a distinguishing feature of KDN expression in ovarian cancer cells, even though the total mol % ratio of KDN/Neu5Ac showed a smaller, yet statistically significant change as noted above.Table IIIQuantitative comparison of the amount of KDN and Neu5Ac present in normal human ovarian tissue, ovarian tumors, and ascites cells from ovarian cancer patientsFractionKDNNeu5AcKDN/Neu5Acμg/g wet tissuemol/100 molNormal ovaryEthanol-soluble0.45351.5Combined precipitates0.111350.10Total0.561700.36Tumor ovaryEthanol-soluble0.77146.3Combined precipitates0.102300.05Total0.872440.41Ascites cellsEthanol-soluble1.39.216Combined precipitates0.16820.22Total1.4691.21.8The 100,000 × g supernatant fraction was prepared after cell homogenization and adjusted to 80% ethanol. The precipitated pellets were recovered after centrifugation, as described under “Experimental Procedures.” The ethanol soluble fraction contained free sialic acid and any conjugated derivatives soluble in 80% ethanol. The combined precipitates represented the 100,000 ×g pellet (100P) from the cell homogenate and the 80% ethanol precipitate, as described in the text. This fraction contained sialic acids conjugated to soluble- and membrane-bound glycoproteins and glycolipids. The results represent the mean values obtained from four samples each of normal and ovarian tumor tissues, and ascites cells were collected from the same four ovarian cancer patients. Open table in a new tab The 100,000 × g supernatant fraction was prepared after cell homogenization and adjusted to 80% ethanol. The precipitated pellets were recovered after centrifugation, as described under “Experimental Procedures.” The ethanol soluble fraction contained free sialic acid and any conjugated derivatives soluble in 80% ethanol. The combined precipitates represented the 100,000 ×g pellet (100P) from the cell homogenate and the 80% ethanol precipitate, as described in the text. This fraction contained sialic acids conjugated to soluble- and membrane-bound glycoproteins and glycolipids. The results represent the mean values obtained from four samples each of normal and ovarian tumor tissues, and ascites cells were collected from the same four ovarian cancer patients. We determined the KDN/Neu5Ac ratio in the ethanol-soluble fraction prepared from different types and stages of ovarian tumors to test the hypothesis that this ratio might correlate with the type and stage of disease. As shown in Table IV, significantly higher KDN/Neu5Ac ratios occurred in all of the ovarian tumors and in the corresponding tumor cells isolated from the ascites fluid of each patient, compared with control normal ovarian tissue. Based on these initial findings, two observations are of particular relevance. First, of the ovarian tissues examined, a mature ovarian teratoma showed a 12-fold increase in the KDN/Neu5Ac ratio. Second, the most dramatic increase overall (22-fold) in this ratio was in ascites cells isolated from a patient with a stage IIIa adenocarcinoma (serous ovarian cyst). A patient with the same type of pathological tumor, but at stage I, showed only a 6.7-fold increase in the KDN/Neu5Ac ratio. These results suggest that a positive correlation exists between the level of free KDN within these ovarian adenocarcinomas and the extent of invasion or stage of malignancy. Although the number of patients in this initial study was too small to draw definitive conclusion regarding the usefulness of the comparative value of free KDN as a potential diagnostic and/or prognostic marker for assessing the malignant state, we are encouraged that the high KDN/Neu5Ac ratios observed in ovarian tumors and in tumor cells recovered from the ascites fluid of these patients may represent a clinical and biochemical indicator of cell anomaly.Table IVQuantitative comparison of the free KDN and Neu5Ac ratio in normal and ovarian tumor tissue and in ascites cells isolated from each patientPathological diagnosisTissue or cell examinedKDN/Neu5Acmol/100 molOvarian mature teratoma (26 y)Tumor ovary18Ovarian mucinous cyst adenocarcinoma (36 y)Tumor ovary5.3Ascites cell0.55Ovarian serous cyst adenocarcinoma, stage I (74 y)Tumor ovary5.6Ascites cell10Ovarian serous cyst adenocarcinoma, stage IIIa (25 y)Tumor ovary6.1Ascites cell33Normal (control) ovary1.5The level of free KDN and Neu5Ac was determined in the ethanol-soluble fraction isolated from the normal ovarian tissue and from the ovarian tumor and ascites of each patient, as described under “Experimental Procedures” and in the legend to Table III. Open table in a new tab The level of free KDN and Neu5Ac was determined in the ethanol-soluble fraction isolated from the normal ovarian tissue and from the ovarian tumor and ascites of each patient, as described under “Experimental Procedures” and in the legend to Table III. The present method that we have developed for identification and quantitative determination of three different types of Sia (KDN, Neu5Ac, and Neu5Gc) has now provided a facile, sensitive, and specific way to study the level and type of these Sia residues in normal and malignant cells. The key to our instrumental analysis (Fig. 3 a) is an HPLC system equipped with a fluorescent detector, as described under “Experimental Procedures.” This method is capable of detecting as little as 1 pmol of KDN and can readily identify and quantitatively determine the amounts of KDN in normal ovarian tissue (Fig. 3 b), ovarian tumor tissue (Fig. 3 c), and ascites cells collected from the same patient (Fig. 3 d). The data in Fig. 3 (b–d) also show that no Neu5Gc was detected in any of the ovarian tumor examined thus far, although this Sia was previously reported to be expressed in other types of human cancers and established tumor cell lines (23Higashi H. Hirabayashi Y. Fukui Y. Naiki M. Matsumoto M. Ueda S. Kato S. Cancer Res. 1985; 45: 3796-3802PubMed Google Scholar, 24Muchmore E.A. Milewski M. Varki A. Diaz S. J. Biol. Chem. 1989; 264: 20216-20223Abstract Full Text PDF PubMed Google Scholar). The central importance of our new findings is 2-fold. First, elevated levels of free KDN in fetal cord red blood cells compared with matched maternal red blood cells is an intriguing observation that may be developmentally related to blood cell formation and the multi- or pluripotential stem cell formation during embryogenesis. To challenge this hypothesis will require a systematic study of KDN levels in different committed stem cells and other differentiated, end stage cells represented by red blood cells, including platelets, neutrophils, monocytes, basophils, B and T cells, and NK cells. It may also be informative to determine the free KDN/Neu5Ac ratios in different hematopoietic malignancies and in the myriad of hematological dyscrasias. Second, the enhanced level of free KDN in ovarian cancer cells compared with normal ovarian tissue leads us to hypothesize that this level could conceivably be used as an “early warning” signal or predictive marker for the detection of the potentially malignant phenotype in ovarian and perhaps other human cancers. This elevation was particularly striking in ascites cells from a patient with a stage III adenocarcinoma compared with a stage I tumor of the same type. Such a marker may also provide an adjunctive way to monitor for recurrence of tumor. It is therefore possible that free KDN levels, like surface expression of the α2,8-polySia glycotope, may be an oncofetal antigen for ovarian cancer, as polySia is for a number of human tumors (reviewed in Ref. 12Troy F.A. Rosenberg A. Biology of the Sialic Acids. Plenum Press, New York1995: 95-144Crossref Google Scholar). These studies raise several important questions that remain to be answered. First, where does free KDN come from, i.e. how is it synthesized? Second, what regulates the intracellular level of KDN? And third, do increased intracellular levels of KDN regulate expression of any of the genes encoding for the enzymes leading to (a) KDN synthesis (KDN synthase); (b) activation (CMP-KDN synthetase); and/or (c) transfer (KDN transferase)? Answers to the latter two questions must await the cloning and detailed examination of the genes and enzymes responsible for KDN activation and transfer. However, our recent studies on the biosynthesis of KDN in trout testis, an organ rich in KDN (25Yu S. Kitajima K. Inoue S. Inoue Y. J. Biol. Chem. 1991; 266: 21929-21935Abstract Full Text PDF PubMed Google Scholar, 26Yu S. Kitajima K. Inoue S. Khoo K.-H. Morris H.R. Dell A. Inoue Y. Glycobiology. 1995; 5: 207-218Crossref PubMed Scopus (24) Google Scholar), have been instructive in addressing the origin of KDN (27Angata T. Identification and Characterization of Enzymes Involved in the Metabolism of KDN and KDN-glycans in Animal Cells.Ph.D. thesis. University of Tokyo, 1997Google Scholar, 28Angata T. Matsuda T. Kitajima K. Troy F.A. Abstract Book for XIXth International Carbohydrate Symposium, CP022. University of California, San Diego1998Google Scholar). These studies have shown that KDN is synthesized from mannose (Man) via the following three sequential reactions:Man+ATP→Man­6­P+ADPMan­6­P+PEP→KDN­9­P+PiKDN­9­P→KDN+PiREACTIONS 1–3Reaction 1, catalyzed by a hexokinase, is the 6-O-phosphorylation of Man to form Man-6-P. Reaction 2, catalyzed by KDN-9-P synthetase, condenses Man-6-P and P-enolpyruvate (PEP) to form KDN-9-P. Reaction 3, catalyzed by a phosphatase, is the dephosphorylation of KDN-9-P to yield free KDN. It is not known if a kinase specific for Man (Reaction 1) and a phosphatase specific for KDN-9-P (Reaction 3) may exist in tissues actively synthesizing KDN. It does appear, however, that the KDN-9-P synthetase (Reaction 2) is at least one enzyme that is uniquely specific in the KDN biosynthetic pathway. This conclusion is based on substrate competition experiments, which have shown that this enzyme is distinct from Neu5Ac 9-phosphate synthetase, the enzyme that catalyzes the condensationN-acetyl-d-mannosamine-6-P and P-enolpyruvate to form Neu5Ac 9-phosphate, the immediate precursor to Neu5Ac (27Angata T. Identification and Characterization of Enzymes Involved in the Metabolism of KDN and KDN-glycans in Animal Cells.Ph.D. thesis. University of Tokyo, 1997Google Scholar,28Angata T. Matsuda T. Kitajima K. Troy F.A. Abstract Book for XIXth International Carbohydrate Symposium, CP022. University of California, San Diego1998Google Scholar). Man-6-P appears to be derived from the phosphorylation of Man (Reaction 1) and not from the conversion of d-fructose 6-phosphate to Man-6-P by phosphomannoisomerase. This conclusion is supported by our findings of free Man in trout ovary and testis, whereas the pool size of free Man-6-P was relatively small (27Angata T. Identification and Characterization of Enzymes Involved in the Metabolism of KDN and KDN-glycans in Animal Cells.Ph.D. thesis. University of Tokyo, 1997Google Scholar, 28Angata T. Matsuda T. Kitajima K. Troy F.A. Abstract Book for XIXth International Carbohydrate Symposium, CP022. University of California, San Diego1998Google Scholar). It was previously reported that the concentration of free Man in normal human serum is approximately 20–50 μm (29Panneerselvam K. Etchison J.R. Freeze H.H. J. Biol. Chem. 1997; 272: 23123-23129Abstract Full Text Full Text PDF PubMed Scopus (57) Google Scholar). In the present study, the concentration of free KDN in adult red blood cells was about 2 μm, whereas in fetal cord red blood cells it was about 5 μm. We have also shown that pig salivary glands actively involved in synthesis of Neu5Gc/Neu5Ac-containing glycoconjugates contain high levels of free KDN. 2S. Inoue, unpublished results. Moreover, we have also recently obtained evidence that the levels of free and bound forms of KDN in cultured mammalian cell lines are increased when the cells are grown in the presence of extracellular Man, but notN-acetyl-d-mannosamine, the precursor of Neu5Ac. 3T. Angata, unpublished results. These findings taken together thus show a positive correlation between the intracellular levels of free Man and free and conjugated KDN and emphasize the importance of additional studies to elucidate the molecular mechanisms regulating KDN expression at both the gene and enzyme level. Our present findings also indicate that the intracellular accumulation of free KDN does not appreciably increase the level of CMP-KDN, presumably because KDN is a poor substrate for CMP-Neu5Ac synthetase (30Terada T. Kitazume S. Kitajima K. Inoue S. Ito F. Troy F.A. Inoue Y. J. Biol. Chem. 1993; 268: 2640-2648Abstract Full Text PDF PubMed Google Scholar). Consequently, only a small proportion of the free KDN is activated to CMP-KDN, thus maintaining the relatively higher level of free KDN in these cells. Our results also suggest that the activity of UDP-GlcNAc 2-epimerase, a key enzyme regulating Neu5Ac synthesis, is not affected by the low, steady-state level of CMP-KDN, even though this sugar nucleotide may control its activity by feedback inhibition. While the reason(s) for higher free KDN levels in fetal cord red blood cells and malignant human ovarian cancer cells remains unclear, further studies on the de novo synthesis, transport, storage, catabolism, and potential oncofetal nature of KDN in normal human cells and their malignant counterparts are required. Such studies should prove of critical importance to fully develop this aspect of the biochemistry, molecular biology, and glycopathology of KDN that has not been previously reported." @default.
• W2071944485 created "2016-06-24" @default.
• W2071944485 creator A5001947000 @default.
• W2071944485 creator A5025720845 @default.
• W2071944485 creator A5029221412 @default.
• W2071944485 creator A5030736937 @default.
• W2071944485 creator A5076459464 @default.
• W2071944485 creator A5076943129 @default.
• W2071944485 creator A5077865886 @default.
• W2071944485 creator A5079718541 @default.
• W2071944485 date "1998-10-01" @default.
• W2071944485 modified "2023-10-17" @default.
• W2071944485 title "Identification of Free Deaminated Sialic Acid (2-Keto-3-deoxy-d-glycero-d-galacto-nononic Acid) in Human Red Blood Cells and Its Elevated Expression in Fetal Cord Red Blood Cells and Ovarian Cancer Cells" @default.
• W2071944485 cites W1490884960 @default.
• W2071944485 cites W1491212204 @default.
• W2071944485 cites W1533919226 @default.
• W2071944485 cites W1560568906 @default.
• W2071944485 cites W1562416468 @default.
• W2071944485 cites W1604742230 @default.
• W2071944485 cites W1608030440 @default.
• W2071944485 cites W1993980994 @default.
• W2071944485 cites W2021647329 @default.
• W2071944485 cites W2024631798 @default.
• W2071944485 cites W2032046378 @default.
• W2071944485 cites W2035194423 @default.
• W2071944485 cites W2038129849 @default.
• W2071944485 cites W2040893426 @default.
• W2071944485 cites W2051841498 @default.
• W2071944485 cites W2069525480 @default.
• W2071944485 cites W2083174993 @default.
• W2071944485 cites W2098717767 @default.
• W2071944485 cites W2150380845 @default.
• W2071944485 cites W2154908299 @default.
• W2071944485 cites W2907517803 @default.
• W2071944485 doi "https://doi.org/10.1074/jbc.273.42.27199" @default.
• W2071944485 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9765240" @default.
• W2071944485 hasPublicationYear "1998" @default.
• W2071944485 type Work @default.
• W2071944485 sameAs 2071944485 @default.
• W2071944485 citedByCount "71" @default.
• W2071944485 countsByYear W20719444852012 @default.
• W2071944485 countsByYear W20719444852013 @default.
• W2071944485 countsByYear W20719444852014 @default.
• W2071944485 countsByYear W20719444852015 @default.
• W2071944485 countsByYear W20719444852016 @default.
• W2071944485 countsByYear W20719444852017 @default.
• W2071944485 countsByYear W20719444852018 @default.
• W2071944485 countsByYear W20719444852019 @default.
• W2071944485 countsByYear W20719444852020 @default.
• W2071944485 countsByYear W20719444852021 @default.
• W2071944485 countsByYear W20719444852022 @default.
• W2071944485 countsByYear W20719444852023 @default.
• W2071944485 crossrefType "journal-article" @default.
• W2071944485 hasAuthorship W2071944485A5001947000 @default.
• W2071944485 hasAuthorship W2071944485A5025720845 @default.
• W2071944485 hasAuthorship W2071944485A5029221412 @default.
• W2071944485 hasAuthorship W2071944485A5030736937 @default.
• W2071944485 hasAuthorship W2071944485A5076459464 @default.
• W2071944485 hasAuthorship W2071944485A5076943129 @default.
• W2071944485 hasAuthorship W2071944485A5077865886 @default.
• W2071944485 hasAuthorship W2071944485A5079718541 @default.
• W2071944485 hasBestOaLocation W20719444851 @default.
• W2071944485 hasConcept C126322002 @default.
• W2071944485 hasConcept C153911025 @default.
• W2071944485 hasConcept C172680121 @default.
• W2071944485 hasConcept C185592680 @default.
• W2071944485 hasConcept C203014093 @default.
• W2071944485 hasConcept C2776557347 @default.
• W2071944485 hasConcept C2776955114 @default.
• W2071944485 hasConcept C2777208419 @default.
• W2071944485 hasConcept C2779234561 @default.
• W2071944485 hasConcept C2780115458 @default.
• W2071944485 hasConcept C2780914630 @default.
• W2071944485 hasConcept C54355233 @default.
• W2071944485 hasConcept C55493867 @default.
• W2071944485 hasConcept C71924100 @default.
• W2071944485 hasConcept C86803240 @default.
• W2071944485 hasConceptScore W2071944485C126322002 @default.
• W2071944485 hasConceptScore W2071944485C153911025 @default.
• W2071944485 hasConceptScore W2071944485C172680121 @default.
• W2071944485 hasConceptScore W2071944485C185592680 @default.
• W2071944485 hasConceptScore W2071944485C203014093 @default.
• W2071944485 hasConceptScore W2071944485C2776557347 @default.
• W2071944485 hasConceptScore W2071944485C2776955114 @default.
• W2071944485 hasConceptScore W2071944485C2777208419 @default.
• W2071944485 hasConceptScore W2071944485C2779234561 @default.
• W2071944485 hasConceptScore W2071944485C2780115458 @default.
• W2071944485 hasConceptScore W2071944485C2780914630 @default.
• W2071944485 hasConceptScore W2071944485C54355233 @default.
• W2071944485 hasConceptScore W2071944485C55493867 @default.
• W2071944485 hasConceptScore W2071944485C71924100 @default.
• W2071944485 hasConceptScore W2071944485C86803240 @default.
• W2071944485 hasIssue "42" @default.
• W2071944485 hasLocation W20719444851 @default.
• W2071944485 hasOpenAccess W2071944485 @default.
• W2071944485 hasPrimaryLocation W20719444851 @default.
• W2071944485 hasRelatedWork W2013415547 @default.
• W2071944485 hasRelatedWork W2034742038 @default.

• next